https://www.selleckchem.com/pr....oducts/a-438079-hcl.
A new era of precision diagnostics and therapy for patients with neuroendocrine neoplasms began with the approval of somatostatin receptor (SSTR) radiopharmaceuticals for positron emission tomography (PET) imaging followed by peptide receptor radionuclide therapy (PRRT). With the transition from SSTR-based gamma scintigraphy to PET, the higher sensitivity of the latter raised questions regarding the direct application of the planar scintigraphy-based Krenning score for PRRT eligibility. Also, to date, the role of SSTR-PET in respon
Like
Comment
Share
